Shah told CNBC-TV18, "Matrix Laboratories is one of the stocks in the midcap pharma that I like. The disclosure will go that we had recommended this particular stock to get invested to our clients and the position might be still intact. I think the stock has given some good run up and going forward the kind of play that is there, Mylan has happened and definitely the numbers were also quite good."
He further added, "The flavour and the focus is now shifting from frontline pharma to midcap pharma, we have seen the kind of performance, be it Matrix or Divis Laboratories, I think all of them have performed quite fantastically. The orderbook is quite healthy. Going forward if the acquisition happens overseas then I think that gives them the inroads for the European markets and the topline and bottomline also increase thereafter. So I would definitely hold on to it."
